InterWest Partners

Bruker said this week it has appointed Joshua Young vice president of investor relations. Young will take over from Stacey Desrochers, who will focus on management of the company's treasury operations.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.